@article {1603875,
	title = {Central neurotoxicity induced by trastuzumab emtansine (T-DM1): a case report},
	journal = {Anticancer Drugs},
	volume = {32},
	number = {10},
	year = {2021},
	month = {2021 11 01},
	pages = {1146-1149},
	abstract = {Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (Her2) - targeted antibody-drug conjugate that is approved for patients previously treated with trastuzumab and a taxane for Her2-positive advanced breast cancer and those who have progressed within 6 months of completion of adjuvant chemotherapy, as well as for patients with residual invasive Her2-positive disease after the completion of adjuvant chemotherapy. Peripheral neuropathy is a common adverse event; however, ocular events have also been described. With the current report we present the case of a 67-year old woman who developed transient grade 2-3 blurred vision after the first T-DM1 infusion, which was complicated with grade 2 diplopia causing vertigo after the second infusion. After extended investigation, this symptomatology was attributed to central neurotoxicity, and gradually resolved after T-DM1 discontinuation.},
	issn = {1473-5741},
	doi = {10.1097/CAD.0000000000001117},
	author = {Papageorgiou, Georgios I and Symeonidis, David G and Tsakatikas, Sergios A and Liatsos, Alexandros D and Douglas, Konstantinos Aa and Douglas, Vivian P and Moschos, Marilita M and Kosmas, Christos}
}
